DOCSLIB.ORG

Ovid MEDLINE(R)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

MeSH headings for Chlamydia trachomatis Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> Search Strategy: -------------------------------------------------------------------------------- 1 exp Chlamydia trachomatis/ 2 ((chlamyd* and trachoma*) or c trachomatis).ti,ab,kf. 3 chlamyd*.ab. /freq=2 or trachomatis.ab. /freq=2 ( 4 2 and 3 5 1 or 4 6 anti-infective agents/ or exp anti-bacterial agents/ or exp anti-infective agents, urinary/ or exp Quinolones/ 7 (anti-biotic* or antibiotic* or antimicrobial* or anti-microbial* or anti-infective or anti- chlamydial or amdinocillin* or amifloxacin or amikacin* or aminocyclitol or amoxicillin* or ampicillin* or azithromycin* or aztreonam* or baicalin or cathelicidin or cefalexin* or cefotaxim* or cefixim* or cefluprenam* or cefodiZim* or cefotetan* or ceftriaxon* or cefuroxim* or cefoperazon* or cefmetazole* or cephamycin* or cephalosporin* or cephamycin* or chaperonin or chloramphenicol* or cilastatin* or cinoxacin or ciprofloxacin* or clarithromycin or clindamycin or cyclosporin* or defensins or dicloxacillin* or difloxacin or coxazosin* or coxycyclin* or enoxacin or erythromycin* or fleroxacin or Fosfomycin* or fropenem* or gentamicin* or Hetacillin* or hexacillin* or isepamicin or josamycin or cactams or Levofloxacin* or lomefloxacin or cymecycline or macrolid* or minocyclin* or miocamycin or miraxid or nalidixic acid or netilmicin* or nifurtoinol or nitrofurantoin or Norfloxacin* or ofloxacin* or oxytetracyclin* or pefloxacin* or penicillin* or piperacillin* or pivampicillin* or rifampicin* or rifamycin* or ritipenem* or roxithromycin or rulid or sitafloxacin* or spectinomycin* or streptomycin* or sulfisoxaZole or tetracyclin* or thiamphenicol or tobramycin* or trimethoprim* or trovafloxacin or vancomycin* or wilprafen or quinolone* or fluoroquinolone*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (770336) 8 6 or 7 9 5 and 8 10 (treat* or therap* or pharmacotherap* or manag*).mp. or (dt or th or tu).fs. 11 9 and 10 12 exp Chlamydia trachomatis/ and Chlamydia Infections/dt [Drug Therapy] 13 11 or 12 14 limit 13 to yr="2006 -Current" 15 limit 14 to (english or french) 16 limit 15 to medline 17 limit 16 to humans 18 child/ not (exp adult/ or adolescent/) 19 17 not 18 20 15 not 16 21 19 or 20 22 limit 21 to (case reports or comment or editorial or letter or news or review) 23 21 not 22 24 limit 21 to (meta analysis or systematic reviews) 25 (((systematic or scoping or integrative) adj2 review) or meta-analysis).mp. 26 21 and 25 27 23 or 24 or 26 28 15 not 16 29 27 or 28 Database: Embase <1974 to 2017 August 04> Search Strategy: -------------------------------------------------------------------------------- 1 *Chlamydia trachomatis/ or exp *chlamydiasis/dt [Drug Therapy] 2 ((chlamyd* and trachoma*) or c trachomatis).ti,ab,kw. 3 chlamyd*.ab. /freq=2 or trachomatis.ab. /freq=2 4 2 and 3 5 1 or 4 6 *anti-infective agents/ or exp *anti-bacterial agents/ or exp *anti-infective agents, urinary/ or exp *Quinolones/ 7 (anti-biotic* or antibiotic* or antimicrobial* or anti-microbial* or anti-infective or anti- chlamydial or amdinocillin* or amifloxacin or amikacin* or aminocyclitol or amoxicillin* or ampicillin* or azithromycin* or aztreonam* or baicalin or cathelicidin or cefalexin* or cefotaxim* or cefixim* or cefluprenam* or cefodiZim* or cefotetan* or ceftriaxon* or cefuroxim* or cefoperazon* or cefmetazole* or cephamycin* or cephalosporin* or cephamycin* or chaperonin or chloramphenicol* or cilastatin* or cinoxacin or ciprofloxacin* or clarithromycin or clindamycin or cyclosporin* or defensins or dicloxacillin* or difloxacin or coxazosin* or coxycyclin* or enoxacin or erythromycin* or fleroxacin or Fosfomycin* or fropenem* or gentamicin* or Hetacillin* or hexacillin* or isepamicin or josamycin or cactams or Levofloxacin* or lomefloxacin or cymecycline or macrolid* or minocyclin* or miocamycin or miraxid or nalidixic acid or netilmicin* or nifurtoinol or nitrofurantoin or Norfloxacin* or ofloxacin* or oxytetracyclin* or pefloxacin* or penicillin* or piperacillin* or pivampicillin* or rifampicin* or rifamycin* or ritipenem* or roxithromycin or rulid or sitafloxacin* or spectinomycin* or streptomycin* or sulfisoxazole or tetracyclin* or thiamphenicol or tobramycin* or trimethoprim* or trovafloxacin or vancomycin* or wilprafen or quinolone* or fluoroquinolone*).mp. 8 6 or 7 9 5 and 8 10 (treat* or therap* or pharmacotherap* or manag*).mp. or (dt or tu).fs. 11 9 and 10 12 limit 11 to yr="2006 -Current" 13 limit 12 to (english or french) 14 limit 13 to (editorial or letter or note or "review") 15 13 not 14 16 (((systematic or scoping or integrative) adj2 review) or meta-analysis).mp. 17 13 and 16 18 15 or 17 19 limit 18 to embase status 20 limit 18 to "pubmed/medline" 21 19 or 20 22 limit 21 to human 23 child/ not (adolescent/ or adult/ or aged/) 24 22 not 23 25 18 not 21 26 24 or 25 27 (case report* or case study or case series).mp. 28 26 not 27 29 remove duplicates from 28 Cochrane #1 [mh "chlamydia trachomatis"] or (chlamyd* and trachoma*):ti,ab,kw or ("c trachomatis"):ti,ab,kw or [mh "chlamydia Infections/dt"] #2 [mh "antibacterial agents"] or [mh quinolones] or (antibiotic* or antibacterial* or "anti-biotic*" or "anti-bacterial*" or antimicrobial* or "anti-microbial*" or "anti-infective*" or amdinocillin* or amifloxacin or amikacin* or aminocyclitol or amoxicillin* or ampicillin* or azithromycin* or aztreonam* or baicalin or cathelicidin or cefalexin* or cefotaxim* or cefixim* or cefluprenam* or cefodizim* or cefotetan* or ceftriaxon* or cefuroxim* or cefoperazon* or cefmetazole* or cephamycin* or cephalosporin* or cephamycin* or chaperonin or chloramphenicol* or cilastatin* or cinoxacin or ciprofloxacin* or clarithromycin or clindamycin or cyclosporin* or defensins or dicloxacillin* or difloxacin or doxycycline or coxazosin* or coxycyclin* or enoxacin or erythromycin* or fleroxacin or Fosfomycin* or fropenem* or gentamicin* or Hetacillin* or hexacillin* or isepamicin or josamycin or cactams or Levofloxacin* or lomefloxacin or cymecycline or macrolid* or minocyclin* or miocamycin or miraxid or nalidixic acid or netilmicin* or nifurtoinol or nitrofurantoin or Norfloxacin* or ofloxacin* or oxytetracyclin* or pefloxacin* or penicillin* or piperacillin* or pivampicillin* or rifampicin* or rifamycin* or ritipenem* or roxithromycin or rulid or sitafloxacin* or spectinomycin* or streptomycin* or sulfisoxaZole or tetracyclin* or thiamphenicol or tobramycin* or trimethoprim* or trovafloxacin or vancomycin* or wilprafen or quinolone* or fluoroquinolone*):ti,ab,kw #3 #1 AND #2 PubMed #1 Chlamydia trachomatis [mesh] OR (chlamydi* [tw] AND trachomo* [tw]) OR "c trachomatis" [tw] #2 anti-infective agents [mesh] OR anti-bacterial agents [mesh] OR anti-infective agents, urinary [mesh] OR Quinolones [mesh] #3 ("anti-biotic* "[Text Word] OR antibiotic*[Text Word] OR antimicrobial*[Text Word] OR "anti- microbial*"[Text Word] OR "anti-infective"[Text Word] OR "anti-chlamydial"[Text Word] OR amdinocillin*[Text Word] OR amifloxacin[Text Word] OR amikacin*[Text Word] OR aminocyclitol[Text Word] OR amoxicillin*[Text Word] OR ampicillin*[Text Word] OR azithromycin*[Text Word] OR aztreonam*[Text Word] OR baicalin[Text Word] OR cathelicidin[Text Word] OR cefalexin*[Text Word] OR cefotaxim*[Text Word] OR cefixim*[Text Word] OR cefluprenam*[Text Word] OR cefodiZim*[Text Word] OR cefotetan*[Text Word] OR ceftriaxon*[Text Word] OR cefuroxim*[Text Word] OR cefoperazon*[Text Word] OR cefmetazole*[Text Word] OR cephamycin*[Text Word] OR cephalosporin*[Text Word] OR cephamycin*[Text Word] OR chaperonin[Text Word] OR chloramphenicol*[Text Word] OR cilastatin*[Text Word] OR cinoxacin[Text Word] OR ciprofloxacin*[Text Word] OR clarithromycin[Text Word] OR clindamycin[Text Word] OR cyclosporin*[Text Word] OR defensins[Text Word] OR dicloxacillin*[Text Word] OR difloxacin[Text Word] OR coxazosin*[Text Word] OR coxycyclin*[Text Word] OR enoxacin[Text Word] OR erythromycin*[Text Word] OR fleroxacin[Text Word] OR Fosfomycin*[Text Word] OR fropenem*[Text Word] OR gentamicin*[Text Word] OR Hetacillin*[Text Word] OR hexacillin*[Text Word] OR isepamicin[Text Word] OR josamycin[Text Word] OR cactams[Text Word] OR Levofloxacin*[Text Word] OR lomefloxacin[Text Word] OR cymecycline[Text Word] OR macrolid*[Text Word] OR minocyclin*[Text Word] OR miocamycin[Text Word] OR miraxid[Text Word] OR nalidixic acid[Text Word] OR netilmicin*[Text Word] OR nifurtoinol[Text Word] OR nitrofurantoin[Text Word] OR Norfloxacin*[Text Word] OR ofloxacin*[Text Word] OR oxytetracyclin*[Text Word] OR pefloxacin*[Text Word] OR penicillin*[Text Word] OR piperacillin*[Text Word] OR pivampicillin*[Text Word] OR rifampicin*[Text Word] OR rifamycin*[Text Word] OR ritipenem*[Text Word] OR roxithromycin[Text Word] OR rulid[Text Word] OR sitafloxacin*[Text Word] OR spectinomycin*[Text Word] OR streptomycin*[Text Word] OR sulfisoxaZole[Text Word] OR tetracyclin*[Text Word] OR thiamphenicol[Text Word] OR tobramycin*[Text Word] OR trimethoprim*[Text Word] OR trovafloxacin[Text Word] OR vancomycin*[Text Word] OR wilprafen[Text Word] OR quinolone*[Text Word] OR fluoroquinolone*[Text Word]) #4 ("anti-biotic* "[Supplementary Concept] OR antibiotic*[Supplementary Concept] OR antimicrobial*[Supplementary Concept]
Recommended publications
  • Double Stage Activity in Aminoglycoside Antibiotics

    Double Stage Activity in Aminoglycoside Antibiotics

    VOL.53 NO. 10, OCT.2000 THE JOURNAL OF ANTIBIOTICS pp.1168 - 1174 Double Stage Activity in Aminoglycoside Antibiotics Kunimoto Hotta, Atsuko Sunada, Yoko Ikeda1" and Shinichi Kondo1" National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan f Institute of Microbial Chemistry, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan (Received for publication July 5, 2000) Fourteen different aminoglycoside antibiotics (AGs) were challenged with aminoglycoside acetyltransferases (AACs) of actinomycete origin in order to examine their 'double stage activity' that is arbitrarily defined as antibiotic activity retainable after enzymatic modification. In kanamycin (KM)-group AGs tested [KM, dibekacin (DKB), amikacin and arbekacin (ABK)], ABKretained activity after acetylations by AAC(3), AAC(2') and AAC(6'). DKBalso retained a weak activity after acetylation by AAC(2'). In gentamicin (GM)-group AGs tested [GM, micronomicin, sisomicin (SISO), netilmicin (NTL) and isepamicin], GM, SISO and NTL retained activites after acetylation by AAC(2'). In neomycin (NM)-group AGs tested [ribostamycin, NM,paromomycin], NMretained activity after acetylation by AAC(6') and AAC(2'). None of astromicin (ASTM)-group AGs tested (ASTMand istamycin B) retained activity after acetylation by AAC(2') and AAC(6'). The activities of acetylated ABK derivatives by AAC(3) and AAC(2') were distinctively high, compared to the others. Streptomyces lividans TK21containing the cloned aac genes were markedly sensitive to AGs that retained activities after acetylation, indicating the substantial effect of 'double stage activity'. Aminoglycoside (AG) antibiotics are generally resistant bacteria was developed by introducing (S)-4- inactivated by acetylation, phosphorylation and adenylyl- amino-2-hydroxybutyryl (AHB) side chain at 1-NH2 of ation due to AG acetyltransferases (AACs), AG KM.
  • WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT

    WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT (51) International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 38/43 (2006.01) A61K 47/36 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61K 38/50 (2006.01) A61K 9/S0 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A61K 33/44 {2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US20 17/039672 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 28 June 2017 (28.06.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (25) Filing Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Langi English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (30) Priority Data: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/355,599 28 June 2016 (28.06.2016) US KM, ML, MR, NE, SN, TD, TG).
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2

    Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2

    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
  • Orally Active Esters of Cephalosporin Antibiotics. Ii

    Orally Active Esters of Cephalosporin Antibiotics. Ii

    VOL. XXXII NO. 11 THE JOURNAL OF ANTIBIOTICS 1155 ORALLY ACTIVE ESTERS OF CEPHALOSPORIN ANTIBIOTICS. II SYNTHESIS AND BIOLOGICAL PROPERTIES OF THE ACETOXYMETHYL ESTER OF CEFAMANDOLE WALTER E. WRIGHT, WILLIAM J. WHEELER, VERLE D. LINE, JUDITH ANN FROGGE' and DON R. FINLEY Lilly Research Laboratories, Eli Lilly and Company Indianapolis, Indiana 46206, U.S.A. (Received for publication August 29, 1979) The synthesis of the acetoxymethyl (AOM) ester of cefamandole (CM) is described. The sparingly soluble ester is shown to be well absorbed orally by mice, but only when administered in solution in a partially non-aqueous vehicle, 50°o propylene glycol. Neither the ester in aqueous suspension nor the sodium salt of CM in solution is well absorbed orally. The rate of oral absorption of the ester from solution is very rapid as shown by the early peak time and shape of the plasma level curve. Oral bioavailability from solution is at least 60% and is ap- parently limited only by hydrolysis or precipitation of a variable portion of the ester dose in the intestinal lumen prior to absorption. Esterification of the carboxyl group of penicillins and cephalosporins can result in significant improvement in the oral absorption of the parent drug. Pivampicillin1), bacampicillin2) and talampicil- lin3J are examples of such successful penicillin derivatives, and the acetoxymethyl ester of cephaloglycin4 and other cephalosporin derivatives') illustrate the applicability of this pro-drug principle to cephalo- sporins. Although the intact esters are biologically inactive, they can be hydrolyzed to the active parent drug either during passage through the intestinal wall or after absorption has occurred6).
  • Guidelines on Urinary and Male Genital Tract Infections

    Guidelines on Urinary and Male Genital Tract Infections

    European Association of Urology GUIDELINES ON URINARY AND MALE GENITAL TRACT INFECTIONS K.G. Naber, B. Bergman, M.C. Bishop, T.E. Bjerklund Johansen, H. Botto, B. Lobel, F. Jimenez Cruz, F.P. Selvaggi TABLE OF CONTENTS PAGE 1. INTRODUCTION 5 1.1 Classification 5 1.2 References 6 2. UNCOMPLICATED UTIS IN ADULTS 7 2.1 Summary 7 2.2 Background 8 2.3 Definition 8 2.4 Aetiological spectrum 9 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 9 2.5.1 Diagnosis 9 2.5.2 Treatment 10 2.5.3 Post-treatment follow-up 11 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 11 2.6.1 Diagnosis 11 2.6.2 Treatment 12 2.6.3 Post-treatment follow-up 12 2.7 Recurrent (uncomplicated) UTIs in women 13 2.7.1 Background 13 2.7.2 Prophylactic antimicrobial regimens 13 2.7.3 Alternative prophylactic methods 14 2.8 UTIs in pregnancy 14 2.8.1 Epidemiology 14 2.8.2 Asymptomatic bacteriuria 15 2.8.3 Acute cystitis during pregnancy 15 2.8.4 Acute pyelonephritis during pregnancy 15 2.9 UTIs in post-menopausal women 15 2.10 Acute uncomplicated UTIs in young men 16 2.10.1 Pathogenesis and risk factors 16 2.10.2 Diagnosis 16 2.10.3 Treatment 16 2.11 References 16 3. UTIs IN CHILDREN 20 3.1 Summary 20 3.2 Background 20 3.3 Aetiology 20 3.4 Pathogenesis 20 3.5 Signs and symptoms 21 3.5.1 New-borns 21 3.5.2 Children < 6 months of age 21 3.5.3 Pre-school children (2-6 years of age) 21 3.5.4 School-children and adolescents 21 3.5.5 Severity of a UTI 21 3.5.6 Severe UTIs 21 3.5.7 Simple UTIs 21 3.5.8 Epididymo orchitis 22 3.6 Diagnosis 22 3.6.1 Physical examination 22 3.6.2 Laboratory tests 22 3.6.3 Imaging of the urinary tract 23 3.7 Schedule of investigation 24 3.8 Treatment 24 3.8.1 Severe UTIs 25 3.8.2 Simple UTIs 25 3.9 References 26 4.
  • Transdermal Drug Delivery Device Including An

    Transdermal Drug Delivery Device Including An

    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al

    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
  • Computational Antibiotics Book

    Computational Antibiotics Book

    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
  • Un Novedoso Enfoque Para El Diseño De Fármacos Antimicrobianos Asistido Por Computadora

    Un Novedoso Enfoque Para El Diseño De Fármacos Antimicrobianos Asistido Por Computadora

    TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño de Fármacos Antimicrobianos Asistido por Computadora Autora: Yasnay Valdés Rodríguez. Tutores: Prof. Dr. Yovani Marrero Ponce. Prof. MSc. Ricardo Medina Marrero. 2005-2006 La ignorancia afirma o niega rotundamente; la ciencia duda… Voltaire (1694-1778) Quiero dedicar este trabajo a todas aquellas personas que me aprecian y desean lo mejor para mi, especialmente a mis padres. A mi padre Dedico este trabajo con mucho amor, por hacerme comprender que siempre se puede llegar mas lejos, y que no hay nada imposible, solamente hay que luchar... A mi madre Por su infinita bondad, por su sacrificio inigualable. A mis familiares Por todo su apoyo y ayuda que me han mostrado incondicionalmente. A mi hermano Por ser mi fuente de inspiración. A la humanidad “...porque si supiera que el mundo se acaba mañana, yo, hoy todavía, plantaría un árbol” Quiero agradecer a todas aquellas personas que me han ayudado a realizar este sueño: A mis padres por todo el sacrificio realizado, y aún parecerles poco, los amo mucho. A mi madre por estar siempre a mi lado en los buenos y malos momentos ayudándome a levantarme en cualquier recaída. A mi padre por guiarme en la vida y brindarme sus consejos siempre útiles, por darme fuerza y vitalidad. A mi mayor tesoro, mi hermano, que me alumbra de esperanza día a día. A mis tías y primos que me ayudaron mucho, aún estando lejos. A mi novio que me apoyo en todas mis decisiones y con paciencia supo ayudarme. A mis tutores y cotutores que siempre me dieron la mano; especialmente a Yovani por su paciencia, a quien debo gran parte de mi formación como profesional por sus exigencias.
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use

    EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use

    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
  • Treating Genitourinary and Pharyngeal Gonorrhoea with Single Dose Ceftriaxone

    Treating Genitourinary and Pharyngeal Gonorrhoea with Single Dose Ceftriaxone

    Genitourin Med: first published as 10.1136/sti.65.1.14 on 1 January 1989. Downloaded from Genitourin Med 1989;65:14-17 Treating genitourinary and pharyngeal gonorrhoea with single dose ceftriaxone J CHRISTOPHERSEN,* A C BOLLERUP,t E FROM,$ J 0 R0NNE-RASMUSSEN,§ K QUITZAUII From the *Department ofDermatovenereology, Gentofte Hospital, Hellerup; the tNeisseria Department, Statens Seruminstitut, Copenhagen; the tDepartment ofDermatovenereology, Marselisborg Hospital, Aarhus; the §Department ofDermatovenereology, Bispebjerg Hospital, Copenhagen; and the IlDepartment ofClinical Research, Roche, Denmark suMMARY The efficacy of ceftriaxone 250 mg given as a single intramuscular dose to treat genitourinary and pharyngeal gonorrhoea is compared with the outcome of the Danish standard treatment for uncomplicated genitourinary gonorrhoea, pivampicillin 1-4 g and probenecid 1 g, both given by mouth. The study comprised 327 patients for whom the diagnosis ofgonorrhoea was made by microscopy of a methylene blue stained smear at their first visit to the clinic and for whom the diagnosis was later confirmed by culture of Neisseria gonorrhoeae. One hundred and seventy patients with genitourinary gonorrhoea (18 with and 152 without concomitant pharyngeal infection) were treated with ceftriaxone. One hundred and fifty seven (17 with and 140 without concomitant pharyngeal infection) were treated with pivampicillin. One week after treatment N gonorrhoeae was isolated from none of 18, 1/152, (1%), 11/17 (65%), and 6/140 (4%) patients, respectively. At a second attendance two weeks after treatment no further treatment failure was found. During the study period, a further 52 patients with pharyngeal infection (with or without concomitant genitourinary infection) that was shown by culture only were treated with a single http://sti.bmj.com/ intramuscular injection of 250 mg ceftriaxone.
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved

    WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved

    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.